par Lonez, Caroline ;Hendlisz, Alain ;Shaza, Leila;Aftimos, Philippe ;Vouche, Michael ;Donckier De Donceel, Vincent ;Machiels, Jean Pascal;Van Den Eynde, Marc;Canon, Jean-Luc;Carrasco, J.;Odunsi, K.;Sahebjam, S.;Rottey, Sylvie;Braun, N.;Verma, B.;Gilham, D.E.;Lehmann, F.F.
Référence Current Research in Translational Medicine, 66, 2, page (53-56)
Publication Publié, 2018-05
Référence Current Research in Translational Medicine, 66, 2, page (53-56)
Publication Publié, 2018-05
Article révisé par les pairs
Résumé : | Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against solid tumors. |